Literature DB >> 18369812

Methods of telomerase inhibition.

Lucy G Andrews1, Trygve O Tollefsbol.   

Abstract

Telomerase is central to cellular immortality and is a key component of most cancer cells although this enzyme is rarely expressed to significant levels in normal cells. Therefore, the inhibition of telomerase has garnered considerable attention as a possible anticancer approach. Many of the methods applied to telomerase inhibition focus on either of the two major components of the ribonucleoprotein holoenzyme, that is, the telomerase reverse transcriptase (TERT) catalytic subunit or the telomerase RNA (TR) component. Other protocols have been developed to target the proteins, such as tankyrase, that are associated with telomerase at the ends of chromosomes. This chapter summarizes some of these recent advances in telomerase inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18369812      PMCID: PMC2423206          DOI: 10.1007/978-1-60327-070-0_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  Telomeres and telomerase: basic science implications for aging.

Authors:  A Ahmed; T Tollefsbol
Journal:  J Am Geriatr Soc       Date:  2001-08       Impact factor: 5.562

2.  Molecular targeting of cancer: telomeres as targets.

Authors:  R Hodes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 3.  Regulation mechanisms of mammalian telomerase. A review.

Authors:  F Ishikawa
Journal:  Biochemistry (Mosc)       Date:  1997-11       Impact factor: 2.487

Review 4.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

Review 5.  Analysis of telomerase activity and detection of its catalytic subunit, hTERT.

Authors:  Sabita N Saldanha; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Anal Biochem       Date:  2003-04-01       Impact factor: 3.365

6.  Reconstitution of human telomerase activity in vitro.

Authors:  T L Beattie; W Zhou; M O Robinson; L Harrington
Journal:  Curr Biol       Date:  1998-01-29       Impact factor: 10.834

7.  Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT.

Authors:  S L Weinrich; R Pruzan; L Ma; M Ouellette; V M Tesmer; S E Holt; A G Bodnar; S Lichtsteiner; N W Kim; J B Trager; R D Taylor; R Carlos; W H Andrews; W E Wright; J W Shay; C B Harley; G B Morin
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

Review 8.  Telomeres, telomerase, and telomerase inhibition: clinical implications for cancer.

Authors:  Ali Ahmed; Trygve Tollefsbol
Journal:  J Am Geriatr Soc       Date:  2003-01       Impact factor: 5.562

  8 in total
  4 in total

1.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells.

Authors:  Ch Lavanya; M K Sibin; M M Srinivas Bharath; M Jeru Manoj; Manjunatha M Venkataswamy; Dhananjaya I Bhat; K V L Narasinga Rao; G K Chetan
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

2.  Τelomerase inhibitors and activators in aging and cancer: A systematic review.

Authors:  Persefoni Fragkiadaki; Elisavet Renieri; Katerina Kalliantasi; Elisavet Kouvidi; Evita Apalaki; Elena Vakonaki; Charalampos Mamoulakis; Demetrios A Spandidos; Aristidis Tsatsakis
Journal:  Mol Med Rep       Date:  2022-03-10       Impact factor: 2.952

Review 3.  From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies.

Authors:  Hironori Adachi; Martin Hengesbach; Yi-Tao Yu; Pedro Morais
Journal:  Biomedicines       Date:  2021-05-14

Review 4.  Oxoisoaporphines and Aporphines: Versatile Molecules with Anticancer Effects.

Authors:  Esteban Rodríguez-Arce; Patricio Cancino; Manuel Arias-Calderón; Paul Silva-Matus; Marianela Saldías
Journal:  Molecules       Date:  2019-12-27       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.